The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2024 | Achieving functional cure in transplant-eligible and transplant-ineligible multiple myeloma
Monika Engelhardt, MD, University Medical Center Freiburg, Freiburg, Germany, shares insights on the developing treatment landscape to achieve functional cures and long-term survival in transplant-eligible and transplant-ineligible patients with multiple myeloma (MM). For transplant-eligible patients, long-term remission is characterized by general fitness, and a good response to stem cell transplantation (SCT), achieved mainly in patients with standard-risk cytogenetics. For transplant-ineligible patients, treatment with daratumumab, lenalidomide, and dexamethasone is highly efficacious, allowing for a transition to a disease state more similar to smoldering multiple myeloma (SMM). This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
